TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04239872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride mouthwash
Description: Sodium fluoride, at a concentration of 0.05% (226 parts per million (ppm) of fluoride), will be used to rinse the mouth for 1 minute and expectorated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoride mouthwash
Description: Sodium fluoride, at a concentration of 0.05% (226 parts per million (ppm) of fluoride), will be used to rinse the mouth for 1 minute and expectorated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium and fluoride mouthwash
Description: Calcium lactate, at a concentration of 150 milimolar, will be used to rinse the mouth for 1 minute and expectorated; immediately after, a sodium fluoride rinse, at a concentration of 0.05% (226 ppm of fluoride), will be used to rinse the mouth for 1 minute, and expectorated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium and fluoride mouthwash
Description: Calcium lactate, at a concentration of 150 milimolar, will be used to rinse the mouth for 1 minute and expectorated; immediately after, a sodium fluoride rinse, at a concentration of 0.05% (226 ppm of fluoride), will be used to rinse the mouth for 1 minute, and expectorated.
Study: NCT01319123

Intervention type: DEVICE
Group type: OTHER
Intervention: Drawtex dressing
Description: The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers
Study: NCT04900272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIPA and companion booklet
Description: Participants will be asked to use the VIPA and accompanying second iteration of the instructional booklet focused on social-isolation. These participants will be surveyed over the phone for 16 weeks (baseline, 2 weeks, 4 weeks, 8 weeks, and 16 weeks) with outcomes measured at each time point.
Study: NCT00430118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vindesine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vindesine

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT04159064

Intervention type: DIAGNOSTIC_TEST
Intervention: Thromboelastometry, Impedance Aggregometry
Description: Study of coagulation changes after cardiac surgery on CPB using Minimal Extracorporeal Circulation
Study: NCT00397579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DT388IL3
Description: Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.
Study: NCT00430118

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01422109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14659
Description: YH14659 capsule by oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel & aspirin
Description: clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
Study: NCT01137786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non ionic contrast media comparator
Description: One time administration for PCI
Study: NCT04125576

Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance imaging(MRI)
Description: magnetic resonance imaging(MRI) will be used to evaluate cerebral blood volume(CBV) of pain network

Intervention type: DIAGNOSTIC_TEST
Intervention: magnetic resonance imaging(MRI)
Description: magnetic resonance imaging(MRI) will be used to evaluate cerebral blood volume(CBV) of pain network
Study: NCT03798262

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten
Description: Tereos

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Whey protein from Nestlé Healthy Science
Study: NCT01137786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non ionic contrast media comparator
Description: one time administration for PCI
Study: NCT04640896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trigger point injection with bupivacaine
Description: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trigger point injection with normal saline
Description: Trigger point injections will be performed within an hour of arrival in post anesthesia care unit, given that the patient has adequately woken up from general anesthesia. Injections will be performed by an anesthesiology provider using a standardized technique under strict aseptic conditions. The trigger point will be located between two fingers, and a 1-2cm sterile needle with a thickness of 25 or 26 gauge inserted at 30 degrees with respect to the skin. Negative aspiration will be confirmed before injecting the study solution. The needle will be withdrawn to the subcutaneous tissue and redirected superiorly, inferiorly, laterally and medially, injecting study solution at each location. Pressure will be applied to the area to ensure hemostasis, and the area dressed with gauze and tape as needed.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lidocaine skin wheal
Description: Patients in the control group will receive a small skin wheal of lidocaine. This will keep the patient blinded to the study group they are in since all patients will receive an injection.~However, this skin wheal is not considered a trigger point injection.
Study: NCT02237664

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous paravertebral analgesia (C-PVB)
Description: Patients will receive continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient-controlled paravertebral analgesia (PC-PVB)
Description: Patients will receive background continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1 with patient demand bolus dose of 3 mL and lockout time of 15 min with a 20 mL h-1 maximum dose, irrespective of their age
Study: NCT00430118

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT00851903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Oral administration. 100mg film-coated tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients continued with metformin as usual oral anti-diabetic treatment.
Study: NCT01475890

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 7000IU per day of vitamin D3 for 12 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once a day for 12 months.
Study: NCT05551130

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restoration
Description: Restorations completed with these materials.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restoration
Description: Restorations completed with these materials.
Study: NCT02979314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Galvanic Vestibular Stimulation
Description: The investigators aim to study the influence of Galvanic Vestibular Stimulation on the brain mechanisms underlying illusory self-motion and its influence on egocentric mental transformation. As a control condition sham stimulation will be applied by the same device within the same participants in different trials. Participants should not note the difference.
Study: NCT03132077

Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Description: surgical intervention for end stage of knee osteoarthritis
Study: NCT02163070

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey drink,
Description: consumption of 220 milliliters of whey drink three times a week,

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey drink fortified with vitaminE
Description: consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: consumption of 400 milligrams of vitamin E three times a week,
Study: NCT02461017

Intervention type: OTHER
Intervention: Assess for Audible Endotracheal Leak
Description: In supine position, the head will be positioned in neutral position. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed and pressure in the inspiratory circuit is slowly increased until an audible leak is heard at the mouth. That pressure will be recorded.

Intervention type: OTHER
Intervention: Assess for Endotracheal Leak with direct visualization under rigid bronchoscope
Description: In the same patient position, a flexible nasal laryngoscope will be inserted and positioned superior to the laryngeal inlet by the surgeon. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed, the pressure in the inspiratory circuit will be increased slowly until a leak around the TT will be visualized by inspecting the supraglottic area for bubbles or air movement around the TT. The peak pressure at which leak is observed physically will be recorded. This is the end of the study.
Study: NCT02318095

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine/nab-Paclitaxel
Description: Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. All chemotherapy administered to study subjects is standard of care. The chemotherapy combination, gemcitabine/nab-paclitaxel, is considered to be a standard-of-care, non-investigational chemotherapy combination; chemotherapy dosing and treatment schedule will be managed by the treating medical oncologist. Restaging will be completed post chemotherapy.

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation therapy
Description: 5 fractions of hypofractionated IGRT or IMRT at 5Gy per fraction will be delivered before surgery. Restaging will be completed post radiation therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Sugical resection
Description: Surgical resection of the pancreas post radiation therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Adjuvant chemotheapy
Description: Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
Study: NCT04561349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task oriented training
Description: Task oriented training consisted of different functional tasks for lower limbs to improve balance and walk. Each task was given 5 minutes Tasks were progressed according to each child's performance. These progressions included increase of repetitions, speed and switching between the tasks. One hour practice of these tasks was advised for home plan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation treatment
Description: Conventional rehabilitation treatment includes mat activities and ROM of all limbs, Lower limb strengthening and stretching, walking, cycling.~Each exercise was performed for 5 minutes. One hour practice of above exercises and thermotherapy for the spastic muscles advised for 10 minutes once a day at home was advised.
Study: NCT01906749

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: 0.5mg once daily orally
Study: NCT02474368

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Study: NCT01906749

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01895530

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Description: The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
Study: NCT03290014

Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: Monitoring of brain activity and respiratory variables during sleep

Intervention type: DIAGNOSTIC_TEST
Intervention: polysomnography
Description: Monitoring of brain activity and respiratory variables during sleep

Intervention type: DIAGNOSTIC_TEST
Intervention: Actigraphy
Description: monitoring daily physical activity for 7 days

Intervention type: DIAGNOSTIC_TEST
Intervention: Actigraphy
Description: monitoring daily physical activity for 7 days

Intervention type: DIAGNOSTIC_TEST
Intervention: Osler test
Description: Evaluation of subjects´ ability to remain awake

Intervention type: DIAGNOSTIC_TEST
Intervention: Osler test
Description: Evaluation of subjects´ ability to remain awake
Study: NCT03420976

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Novel Supplement Based Therapy
Description: Supplements and Dosage:~Detox Support: Liver-G.I. Detox BID for 30 days GI Support: L-Glutamine Powder 2 scoops QD for 35 days Microbial Balance: MicroDefense 1 capsule QD for 49 days Microbial Balance: A.C. Formula II 2 capsules BID for 49 days Probiotic: Probiotic-5 1 capsule QD for 49 days Digestive Enzymes: Digestive Enzymes Ultra with Betaine HCl As needed up to 6 longer term
Study: NCT00686127

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidoderm patch
Description: 1 patch was applied topically to the affected site(s) for 12 hours each day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: 1 patch was applied topically to the affected site(s) for 12 hours each day.
Study: NCT04584177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm-hand BOOST program
Description: The arm-hand boost program is provided 1 hour/day, 5x/week for 4 weeks, on top of their usual care program. The focus of the boost program is on scapula-setting, core-stability when reaching, movements with 30-60° flexion/abduction in shoulder, fine manipulation and integration in complex ADL tasks. Additionally, patients exercise 1 hour per week using the Armeo Power (Hocoma). Therefore, the additional arm-hand boost program consists of 24 one-hour sessions, provided over four weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Arm-hand BOOST program
Description: The arm-hand boost program is provided 1 hour/day, 5x/week for 4 weeks, on top of their usual care program. The focus of the boost program is on scapula-setting, core-stability when reaching, movements with 30-60° flexion/abduction in shoulder, fine manipulation and integration in complex ADL tasks. Additionally, patients exercise 1 hour per week using the Armeo Power (Hocoma). Therefore, the additional arm-hand boost program consists of 24 one-hour sessions, provided over four weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control program
Description: A dose-matched program of strengthening exercises for the lower limbs and general reconditioning

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control program
Description: A dose-matched program of strengthening exercises for the lower limbs and general reconditioning
Study: NCT04391933

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI 3 tesla
Description: MRI of colon cancer. Sensitivity, specificity, positivity predictive values and negative predictive values are calculated form the histopathological surgical specimen. This will be the endpoint for both CT and MRI.
Study: NCT02411552

Intervention type: BEHAVIORAL
Intervention: physical activity
Description: 4 strategies are: (1) increased activity time during physical education class, (2) active recess, (3) opportunities for activity before and after school, and (4) active classroom breaks

Intervention type: BEHAVIORAL
Intervention: physical activity
Description: 4 strategies are: (1) increased activity time during physical education class, (2) active recess, (3) opportunities for activity before and after school, and (4) active classroom breaks
Study: NCT01832259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib, 800 mg, orally daily for 28 days prior to radical prostatectomy.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet orally, daily for 28 days prior to radical prostatectomy.
Study: NCT01043380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]
Description: Zetia 10 mg/dl + Lipitor. The dosage of Lipitor will be titrated up to a maximum of 20 mg/day with a treatment goal of lowering LDL-C below 70 mg/dl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipitor (Atorvastatin) monotherapy
Description: The dosage will be titrated up to a maximum of 20 mg/day, which is the highest approved regimen by the Ministry of Health, Labor and Welfare of Japan, with a treatment goal of lowering LDL-C below 70 mg/dl.
Study: NCT04271462

Intervention type: OTHER
Intervention: Comparing two CO2 absorbers in the ventilator circuit
Description: General anaesthesia will be induced with a standardised regimen (propofol 0.8-2.5 mg·kg-1, sufentanil 0.2 - 0.5 µg·kg-1 and rocuronium 0.5 - 1 mg·kg-1). After tracheal intubation, anaesthesia will be maintained with sevoflurane targeted at 1 MAC end tidal concentration (corrected for age using the formula by Mapleson) in 40% O2. Different ventilator settings will be compared for 30 minutes (in randomised order):~I. Sodalime, FGF 2.0 L min-1. II. Amsorb Plus®, FGF 2.0 L min-1. III. Soda lime, FGF, 0.5 L min-1. IV. Amsorb Plus®, FGF 0.5 L min-1. FGF=fresh gas flow.
Study: NCT01091961

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative ACEi/ARB management
Description: Patients will either hold their chronic ACEi/ARB medication for at least 24 hours prior to surgery, or continue to take the ACEi/ARB medication up to and including the day of surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative ACEi/ARB management
Description: Patients will either hold their chronic ACEi/ARB medication for at least 24 hours prior to surgery, or continue to take the ACEi/ARB medication up to and including the day of surgery
Study: NCT02247869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dose dense ABVD
Description: dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen~* Doxorubicin 25 mg/m2 i.v. day 1 and 8~* Bleomycin 10 mg/m2 i.v. day 1 and 8~* Vinblastine 6 mg/m2 i.v. day 1 and 8~* Dacarbazine 375 mg/m2 i.v. day 1 and 8~Granulocyte colony-stimulating factor (G-CSF): days 9 to 14
Study: NCT03624738

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure
Description: Patients with redo cardiac surgery 1: femoral artery-femoral vein cardiopulmonary bypass (CPB) in order to achieve cardiac decompression prior to sternotomy.~Patients with redo cardiac surgery 2: only conventional aortobicaval cannulation will be used

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Procedure
Description: Patients with redo cardiac surgery 1: femoral artery-femoral vein cardiopulmonary bypass (CPB) in order to achieve cardiac decompression prior to sternotomy.~Patients with redo cardiac surgery 2: only conventional aortobicaval cannulation will be used
Study: NCT02418130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03539432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 MG
Description: Gemfibrozil capsules (600 mg) taken twice per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Microcrystalline cellulose powder packaged in capsules identical to the experimental medication
Study: NCT01381094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: oral dose administered once daily for 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: oral dose administered once daily for 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: oral dose administered once daily for 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-6548
Description: oral dose administered once daily for 42 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral Placebo administered once daily for 42 days